DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Roberts AW, Seymour JF, Brown JR et al.
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease.
Journal of Clinical Oncology 2012;
30: 488-496
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.